Natco Pharma has successfully completed a strategic acquisition that strengthens its international operations. The pharmaceutical company has acquired the remaining 49% stake in PT Natco Lotus Farma, bringing its total ownership to 100%.

Transaction Details

The acquisition was completed through a cash transaction valued at IDR 14.08 billion, which translates to approximately ₹7.7 crores. This strategic move represents Natco Pharma's commitment to expanding its footprint in international markets.

Strategic Significance

With this acquisition, Natco Pharma has achieved complete control over PT Natco Lotus Farma, its Indonesian operations. The transaction eliminates any minority shareholding in the subsidiary, providing the company with full operational control and decision-making authority over its Indonesian business activities.

The completion of this deal marks an important milestone in Natco Pharma's international expansion strategy, particularly in the Southeast Asian pharmaceutical market. Full ownership of the Indonesian subsidiary is expected to streamline operations and enhance the company's ability to execute its business strategies in the region.

Natco Pharma Limited has announced a board meeting scheduled for February 12, 2026, to deliberate on key financial matters for the third quarter of fiscal year 2026. The pharmaceutical company informed stock exchanges about the upcoming meeting through an official communication dated January 28, 2026.

Board Meeting Agenda

The board meeting will address two primary items of business that are crucial for shareholders and market participants:

The meeting represents a significant milestone as the company prepares to disclose its third-quarter performance and evaluate the possibility of distributing additional returns to shareholders through an interim dividend.

Trading Window Restrictions

In adherence to SEBI (Prohibition of Insider Trading) Regulations, 2015, Natco Pharma has implemented mandatory trading restrictions. The trading window for company securities will remain closed from January 29, 2026 to February 14, 2026, both days inclusive.

This restriction applies to all employees, connected persons, and their immediate relatives, ensuring compliance with insider trading prevention measures during the period leading up to and following the financial results announcement.

Regulatory Compliance

The board meeting notice has been submitted under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, demonstrating the company's commitment to transparent corporate governance. The communication was signed by Chekuri Venkat Ramesh, Company Secretary and Compliance Officer, and submitted to both BSE Limited and National Stock Exchange of India Ltd.

The company trades on BSE under scrip code 524816 and on NSE under the symbol NATCOPHARM. Natco Pharma is headquartered at 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad, Telangana, and operates under CIN L24230TG1981PLC003201.